You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Optimizing brain penetrance of caspase-6 inhibitors to treat neurodegenerative diseases
SBC: ELGIA THERAPEUTICS, INC. Topic: RPROJECT SUMMARY/ABSTRACT The cysteine protease caspase-6 (Casp6) has been associated with neurodegenerative diseases for over fifteen years. In Alzheimer’s disease (AD), Casp6 is colocalized with amyloid plaques and tau tangles in human brain, and both human and animal model data indicate that activated Casp6 contributes to neuronal inflammation, neurodegeneration, and cleavage of proteins to to ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Identification of Mixed NOP/mu partial agonists as lead compounds for treatment ofmethamphetamine use disorder
SBC: PHOENIX PHARMALABS, INC. Topic: NIDAAbstract Currently, clinically used drug abuse medications exist for treatment of addiction to opiates, alcohol, and nicotine, but not psychostimulants, such as methamphetamine (METH). Compounds that co-activate both nociceptin opioid peptide (NOP) and mu receptors have potential for treatment of drug abuse. In particular, buprenorphine, a partial mu agonist/kappa antagonist, which also acts as a ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Glove-based Tactile Streaming of Braille Characters and Digital Images for the Visually Impaired
SBC: HAPTX INC Topic: NEIThis project will achieve a computerized system that supplies digital content, both lexical and graphical, suitable for children, students and working adults of the Visually Impaired (VId) community, to increase their autonomy and potentiate their Quality of Life and societal contribution. While there is notable academic research, such as a high-density pin display tablet, there is no commercial, ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A decellularized porcine placenta matrix hydrogel for management of radiation-induced proctitis
SBC: Briopryme Biologics, Inc. Topic: 102PROJECT SUMMARY Radiation therapy is a widely used treatment modality for pelvic malignancies such as prostate and cervical cancer; however, the high doses needed to confer therapeutic benefit often inflict significant damage on the normal issue in and surrounding the radiation field. The most frequent complication of pelvic radiation is proctitis, which nearly all patients experience acutely and ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Testing the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsy
SBC: NEURAEGIS INC Topic: 103AbstractEpilepsy is the most prevalent neurological diseases after migraines. Current antiepileptic drug treatments mainly attempt to reduce excitation or enhance inhibition in order to control seizures. Unfortunately, such therapeutics result in a number of undesirable side-effects, and demonstrate limited efficacy against drug- resistant cases of epilepsy. So far, no treatment has been developed ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Clusterin Targeting of Ocular Surface Disease
SBC: PROTERIS BIOTECH, INC. Topic: NEIPROJECT SUMMARYThe ocular surface (OcS) comprises the stratified squamous epithelia of the cornea/conjunctiva, its adnexa, and the overlying tear film. OcS disease disrupts the normal developmental progression, maturation, and turnover of OcS epithelia, causing “epitheliopathy” characterized by cell damage, barrier disruption and programmed cell death. OcS disease initiated by tear dysfunction ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Assessment of Deep Learning Classification Methods for Parkinsonism
SBC: AUTOMATED IMAGING DIAGNOSTICS LLC Topic: 108SUMMARY The growth rate in the number of people diagnosed with Parkinsonism is substantial. Estimates indicate that from 1990 to 2015 the number of Parkinsonism diagnoses doubled, with more than 6 million people currently diagnosed. By 2040, there will be between 12-14 million people diagnosed with Parkinsonism. Parkinson’s disease (PD), multiple system atrophy Parkinsonian variant (MSAp), and p ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Audiom: Developing an Indoor Non-Visual Mapping System
SBC: XR NAVIGATION INC Topic: NEIProject Abstract Indoor navigation for blind and visually impaired individuals (BVIs) within unfamiliar locations is typically an incredibly anxiety-provoking and stressful experience for numerous reasons, e.g., inaccessible signage including directories and venue maps, and if braille signs do exist, they are difficult to find, lack directional information, and are useless to the BVIs who do not r ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
MT-125 for the Therapeutic Treatment of Glioblastoma
SBC: MYOSIN THERAPEUTICS INC. Topic: 102PROJECT SUMMARYAn area of significant unmet need is the treatment of glioblastoma (GBM), an aggressive, fast-growing and lethal brain cancer that represents 48% of all malignant brain tumors. Untreated, GBM is fatal within three months, and due to its high rate of recurrence and invasive nature, the current standard of care, consisting of safe maximal tumor resection, radiation therapy and chemoth ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Agents Targeting Cryptococcal Infections
SBC: Quercus Molecular Design, LLC Topic: NIAIDCryptococcus species are a clinically important group of opportunistic fungal pathogens that can cause life threatening disease, particularly in the immunocompromised patient population. Historically, this has involved patients with advanced HIV, but is becoming more prevalent in other immunovulnerable populations. The primary pathogens, C. neoformans and C. gattii, are ubiquitous in the environme ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health